MedTrace Logo

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

NCT01310881 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2011-11-21

No results posted yet for this study

Summary

This is a subject single blinded, randomized, placebo-controlled, single dose, first-time-in-human study with three or more ascending cohorts.

Conditions

Interventions

DRUG

NSI-189 Phosphate

Once daily oral administration

Sponsors & Collaborators

  • Neuralstem Inc.

    lead INDUSTRY

Principal Investigators

  • Karl Johe, PhD · Neuralstem Inc.

  • David Han, MD · California Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01310881 on ClinicalTrials.gov